← Back to headlines
Autolus Therapeutics Becomes Less Speculative as AUCATZYL Revenue Builds
Autolus Therapeutics (AUTL) is shedding its speculative status as revenue from its drug AUCATZYL continues to grow.
17 Jun, 15:16 — 17 Jun, 15:16
Sources
Showing 1 of 1 sources
